Molecular mechanisms of insulin resistance in arterial hypertension
Novo Nordisk the Danish maker of Ozempic, Wegovy and Rybelsus reported $31.1 billion in revenue from these three drugs in 2024, up from $11.9 billion in 2022
Within the late-stage pipeline assets (around half of which are targeting weight management), eight are oral ones, aiming to solve the inconvenience of injections, and approximately 20 are dual-target or triple-target, aiming to achieve superiority in clinical effectiveness
doi: 10.1186/s12902-020-0542-5
Eisenberg, D., Shikora, S.A., Aarts, E., et al
Our team creates individualized plans that combine medication with nutrition guidance and exercise protocols tailored to your specific needs